user-avatar
Reuters

Capricor's Duchenne treatment fails to secure FDA approval; shares sink

AI Market Summary
Capricor shares fell 77% after the FDA rejected deramiocel for Duchenne muscular dystrophy, citing insufficient evidence. The decision is a company-specific setback and may weigh on sentiment toward speculative biotech names, but it has no broad market read-through. Short-term impact is likely contained to Capricor and related Duchenne assets.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.47%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
The cell therapy was intended to preserve upper-limb function in patients with Duchenne muscular dystrophy. In July, FDA advisers voted 9-3 that the evidence for its efficacy in heart disease was insufficient.